Intra-day and inter-day precision and method recovery of MPA-DNPH derivative.a
1.1. Steroid hormones and hormonal contraceptive drugs
Generally, progestogens, i.e. progesterone in combination with oestradiol esters, are used primarily in the treatment of menstrual irregularities to maintain endangered pregnancies. Their derivatives are orally active medroxyprogesterone acetate including hydroxyprogesterone caproate, chlormadinone acetate, megestrol acetate. Naturally occurring glucocorticoids are often used in medicine such as cortisone, hydrocortisone, prednisone and prednisolone (Fig. 1). Depot-medroxyprogesterone acetate (Depot-MPA) is commercially available and commonly known as a hormonal contraception used by women. It is a synthetic steroid hormone, which mimics natural progesterone, but its contraceptive activity has been shown to be about 30 times higher. Depot-MPA is widely used by intramuscular administration for long-term contraception [1-3].
1.2. Determination of MPA in hormonal contraceptive drugs
Analysis of MPA in plasma or serum has been performed to study its pharmacokinetics and to monitor its residual levels in cancer patients after oral or intramuscular administration [4,5]. Numerous recent researches for this analysis have been reported concerning the method sensitivity and selectivity in association with various instruments including GC, HPLC and others [6-15]. However, each of which had their advantages and disadvantages. Therefore, development and validation of the method for MPA analysis in spiked blood plasma using internal standard by HPLC method with specific derivatizing agents and clean-up by solid-phase extraction have been carried out. The method sensitivity obtained is suitable for pharmacokinetics study of MPA.
Normally, the levels of MPA found in plasma range from 1.75 to 9.0 ng/mL . Formerly, the measurement of MPA in a plasma sample was mostly carried out by radioimmunoassay (RIA) . Trace analysis of MPA in dog plasma was achieved using cyclohexane extraction, followed by heptafluorobutylic anhydride derivatization and gas chromatography with electron capture detector (GC-ECD). However, this procedure could not be applied for MPA analysis in human plasma due to its high matrix interference. Attempts have been made to optimize the methods for MPA analysis using small amounts of plasma samples [7,8]. Quantitative analysis of MPA in plasma by HPLC with ultraviolet (UV) detection was also carried out, but did not give satisfactory detection limit [9,10]. The high sensitivity of the GC-MS has also been used to monitor the MPA level in human serum . This procedure used trifluoroacetic anhydride derivatization of the extracted portion after SPE and gave the detection limit down to 0.5 ng/mL.
Although, HPLC-UV analysis of MPA in plasma has been performed, but its sensitivity was about 5 ng/mL . In order to enhance both selectivity and sensitivity, recent method development and validation of MPA analysis has been focused on HPLC separation with various detection systems. HPLC with chemiluminescence detection was used to trace MPA in serum via 4-(N,N-dimethylaminosulphonyl) -7-hydrazino-2,1,3-benzoxadiazole as a fluorogenic agent . Recently, MPA analysis in plasma sample has been conducted by liquid chromatography-electrospray ion trap mass spectrometry (LC-MS/MS) after liquid phase extraction and this gave 10 times higher sensitivity than GC-MS [11,14].
From these reviews, both GC-ECD and HPLC-UV did not give sensitivity high enough for MPA analysis in pharmacokinetic studies. In clinical aspects, the RIA method has a rather high sensitivity but sometimes gives positive result due to metabolite interference. Both GC-MS and LC-MS/MS are methods of choice with high selectivity and sensitivity, but may be considerably inconvenient for routine analysis due to the high instrument cost. The HPLC with amperometric detector (AD) would be a highly sensitive tool. From the molecular structure, MPA is a ketone steroid in which the ketone group can undergo reduction. Since the reduction is normally easily interfered by oxygen molecule dissolved in mobile phase, this may be a problem . Hydrazines including 2,4-dinitrophenyl hydrazine (DNPH) have been introduced as an electroactive labeling reagent for carbonyl compounds . Until now there is no report of the derivatization of MPA with DNPH (Fig. 2). From the chemical structures condensation reaction can occur between the keto group of MPA and DNPH to give the MPA-hydrazone which can be detected by HPLC-AD. The optimum conditions of DNPH derivatization with MPA were studied. Therefore, development and validation of the method for MPA analysis in spiked blood plasma using prednisolone (P) as internal standard (I.S.) by HPLC-AD after derivatization with DNPH and clean-up by solid-phase extraction have been carried out. The method sensitivity obtained is suitable for pharmacokinetic study of MPA.
2. HPLC-AD analysis of MPA in human plasma: A case study
2.1. Reagents, standard solution and plasma sample
Medroxyprogesterone acetate (MPA), 99.27%, used as working standard was obtained from A.N.B. Laboratory Co. Ltd. (Thailand). Predinisolone was an analytical reagent (A.R.) grade from Sigma (Germany). 2,4-Dinitrophenylhydrazine (Fluka, Switzerland) was also of A.R. grade. Methanol (MeOH, Merck, Germany), acetonitrile (ACN, Merck, Germany), di-potassium hydrogen phosphate-3-hydrate (BDH, England) and potassium dihydrogen phosphate (BDH, England) were of HPLC grade. Other chemicals used were also A.R. grade including hydrochloric acid (Merck, Germany).
Standard stock solution (500 mg/mL) of MPA was prepared in methanol. Dilute standard solutions of MPA were also prepared in methanol. The 2,4-dinitrophenylhydrazine stock solution used as a labeling reagent (1,000 mg/mL) was prepared by dissolving the hydrazine in 1.2 mL concentrated HCl prior to adjusting the final volume to 25 mL with methanol.
Stock phosphate solution (2 M) was prepared from sodium dihydrogen phosphate monohydrate (NaH2PO4.H2O) in deionized water. A buffer solution of 30 mM potassium dihydrogen phosphate (KH2PO4), pH 3.0 was made by dissolving KH2PO4 in deionized water and adjusting to pH 3.0 with 6 M orthophosphoric acid (H3PO4). Mobile phase was prepared and used to optimize the separation of the mixture of MPA-DNPH and P-DNPH derivatives by amperometric detection (HPLC-AD). The suitable solvent system was composed of ACN : MeOH : 30 mM KH2PO4 (pH 3.0) in the ratio of 39 : 39 : 22 by volume according to Snyder et al. . The mobile phase was filtered through nylon membrane (0.45 m, 47 mm) and degassed for 15 min in ultrasonic bath before use. Sep-pak C18 cartridge, 100 mg (Waters Associates, U.S.A.) was used.
Human blood plasma samples were kindly obtained from the Blood Bank, Srinagarin Hospital, Khon Kaen University, Khon Kaen, Thailand.
2.2. Instruments and apparatus
HPLC system (Perkin Elmer, U.S.A.) used in this study included LC200 HPLC pump with electrochemical detector (Coulochem II, ESA, U.S.A.). The standard analytical cell (ESA 5011, U.S.A.) consisted of porous graphite working electrode, palladium reference electrode and platinum counter electrode. The analytical column used was stainless steel tube packed with Hypersil ODS, 5 m particle size (125 x 4.0 mm i.d., Agilent, U.S.A.). Integrator model1022 (Perkin Elmer, U.S.A.) was used. UV-Visible spectrophotometer (Cecil 3000, England) was also used. Analytical balance (AE 200) and pH meter (Delta 350) were from Mettler (U.S.A.). SPE manifold-12 place vacuum manifold (Lida, Germany) was used. Autopipette (Eppendorf, Germany) with volume adjustments was used throughout the experiment.
2.3. Method development and validation
Derivatization of MPA with DNPH
Study on the hydrazine derivatization of MPA was carried out using 2,4-dinitrophenylhydrazine (DNPH). The standard solution of MPA (10 mg/mL) was reacted with an excess amount of DNPH for an hour. The MPA-DNPH derivative was then injected into HPLC with detection at 375 nm . The MPA-DNPH derivatives obtained from reacting 0.1 mg MPA with various concentrations (12.5, 25.0, 75.0 and 100.0 mg/mL) of DNPH solution in a 2.5 mL capped vial were used to study the effect of DNPH concentration and reaction time.
Prednisolone (P) was also tested for derivatization with DNPH and was used as I.S. There should be a single peak and no overlap with any interfering peaks in the sample. The P-DNPH derivative was obtained from the reaction of 0.10 g DNPH in 10 mL MeOH and 0.48 mL concentrate HCl with 0.05 g prednisolone . The reaction mixture was placed on a heated water bath at 60oC for 30 min, allowed to cool down to room temperature and deionized water (60 mL) was added until the derivative product had completely precipitated. The derivative product was filtered through a glass filter and washed with 5 mL 2 M HCl twice, followed by 50 mL deionized water. It was then recrystallized in a mixture of chloroform and methanol prior to use.
Solid-phase extraction of MPA-DNPH derivative
The clean up method using solid-phase extraction (SPE) was found to be a critical step for plasma sample both before and after derivatization with DNPH. Spiked standard plasma (MPA 6 ng/mL) was extracted by Sep-pak C18 cartridge using a mixture of MeOH : H2O as extraction solvent. The C18 cartridge was first washed with 2 mL MeOH and followed by 2 mL water. The spiked plasma (2 mL) was added into the cartridge and then washed with 2 mL water, followed by 250 mL 50%(v/v) MeOH (3x), and the final elution was made with 1 mL MeOH. The MPA extract portion was kept for derivatizing with DNPH. The solution of DNPH containing 0.1 mg was added into the MPA extract portion and allowed to stand for 30 min, followed by 0.9 mL water and 0.2 mL solution of P-DNPH (10 ng/mL). The sample of the derivative mixture was then introduced into the cartridge followed by 3 times rinsing with 1 mL 50%(v/v) MeOH. The cartridge containing MPA- and P-DNPH products was washed by 250 mL 50%(v/v) MeOH (3x) and again allowed to stand for 15 min before elution by 1 mL MeOH. The elute was then dried over a stream of N2, re-dissolved in 60 mL MeOH, then 40 mL MeOH added and 60 mL was injected into the HPLC system.
Analysis of MPA-DNPH by RP-HPLC-AD
The separation of both MPA- and P-DNPH derivatives was carried out on Hypersil ODS column by HPLC-AD (0.85 V) using an electrolyte solvent system as mobile phase with a flow-rate of 1 mL/min. The mobile phase of ACN : MeOH : 30 mM KH2PO4 (pH 3.0) (30 : 39 : 22, v/v/v) was used in this experiment after optimization of buffer concentration, pH and organic modifier. Both MPA standard solution and MPA spiked plasma sample were prepared at the concentrations of 0.5, 1, 2, 4, 6 and 8 ng/mL.
Method sensitivity of MPA analysis in spiked plasma sample
Various concentrations of MPA spiked in a plasma sample with 10 ng/mL P-DNPH as I.S. were extracted by Sep-pak C18 cartridge, and run by HPLC-AD (0.85 V) [20,21]. Limit of detection (LOD) is the concentration of MPA giving a peak height 3 times the baseline noise (3SD) and the limit of quantitation (LOQ) is defined as 10SD. The standard curve was obtained from the concentrations of 0.5, 1, 2, 4, 6, 8 and 10 ng/mL. The accuracy and precision including recovery were determined at three concentration levels (1, 4 and 8 ng/mL) of the spiked plasma standard.
3. Results and discussion
For method development, studies on derivatization of some hydrazines with MPA had been carried out in acidic solution . It was found that DNPH is a suitable reagent. Many internal standards having similar core structure which is derivatized with DNPH were also investigated by the same manner . Prednisolone was found to be the most suitable ketosteroid and its derivatized solid product was prepared. It was eluted along with the MPA-DNPH and was used as I.S. throughout the experiment.
Effects of derivatization time and concentration of DNPH for MPA analysis were studied. The DNPH concentrations used were 12.5, 25, 75 and 100 mg/mL. MPA (100 ng/mL) was used to react with various concentrations of DNPH in the ratio of 1 : 1 at room temperature and their reaction times were also done up to 180 min (Fig. 3). It was found that 75 mg/mL of DNPH gave the highest peak area within 120 min derivatization time. In this study, the derivatization time of 30 min wasenough, since the signal output was not significantly different from that of 120 min derivatization.
The effect of temperature for 30 min derivatization was also investigated using 100 ng/mL MPA and 75 mg/mL DNPH in acidic solution. There seemed to be no effect of temperature, except a linear increase of peak area when the reaction was performed at room temperature (Fig. 4). Thus, the reaction was rapidly completed at room temperature.
Concerning on RP-HPLC-AD analysis, the optimization conditions of the HPLC-AD for MPA-DNPH analysis were then investigated. Effects of pH (3-6) and buffer concentration (10-40 mM) on mobile phase (ACN : phosphate buffer) were carried out. It was found that the optimum buffering system was at pH 3.0 and 30 mM phosphate buffer (data not shown). In addition, the ratios of organic solvents were investigated and a good separation was obtained with the mobile phase of ACN : MeOH : 30 mM phosphate buffer (pH 3.0) at the ratio of 39 : 39 : 22 by volume.
Figure 5 shows the hydrodynamic voltammogram (HDV) of MPA- and P-DNPH derivatives. The optimum potential that gave the highest peak area was around 0.8-0.9 V for both derivatized products, and 0.85 V was used in this study.
For method validation, the method limits for detection and quantitation were found to be 0.2 and 1.0 ng/mL with lower 15% precision and 80 - 120% accuracy, respectively. In Table 1, the results for intra-day and inter-day precision were 5.05 and 11.5 %RSD, respectively. The intra-day accuracy ranged from 102.2 - 109.5%. The average recovery was found to be 102.9 + 4.4%. It was found that this electrochemical detection was considerably selective and gave a working range of 1.0 - 10.0 ng/mL with linear regression: y = (3.17 + 0.12) x – (0.67 + 0.03), r2 = 0.9985 for
|Mean + SD||5.05 + 2.7||11.5 + 3.4||102.9 + 4.4|
Since the method sensitivity of MPA analysis was the main objective of this study, it has been shown that the clean-up step, using the SPE method for MPA spiked in human plasma sample, was necessary probably due to both the reagent used and the sample interference matrices (Fig. 6, a-d). The solution of MPA-DNPH derivative products with excess DNPH was not clean enough, so it must be added through the Sep-pak cartridge before being separated on the HPLC-AD system. Without the clean-up step, there might be trouble for the HPLC column used, which may affect the analytical sensitivity as well. This is the first report of the use of DNPH as an electroactive labeling reagent for MPA analysis. Development and validation of the HPLC-AD of the derivatized product were then carried out. The MPA-DNPH was completely separated from the I.S. within a suitable analysis time (Fig. 6, a-d).
|Instrument||Extraction method||Sample size (mL)||LOD (ng/mL)||Reference|
|HPLC-ADf||solid phase||2||0.2||This work|
The plasma sample size used in this study was still rather high (2 mL) for clinical aspects when compared with other reports [11,13,14], giving LOD and LOQ of 0.2 and 1.0 ng/mL, respectively. Thus, the developed method with electrochemical detection has sufficiently high sensitivity when compared with other methods, except for the tandem MS, as shown in Table 2. It is, however, satisfactory for pharmacokinetic study of trace MPA in plasma sample, especially in the case of contraceptive administration with very low dose. Since it is rapid procedure and inexpensive, this technique is suitable for routine analysis of the MPA content in most pharmaceutical products and blood samples.
A specific and sensitive method is presented for the analysis of medroxyprogesterone acetate (MPA) in human plasma using reversed phase high-performance liquid chromatography (HPLC) with amperometric detection. The blood sample spiked with trace amount of MPA was cleaned up to remove natural interfering matrices by solid-phase extraction (SPE). The MPA extract was then derivatized with 2,4-dinitrophenylhydrazine (DNPH) as an electroactive agent. The MPA-DNPH derivative was re-extracted using SPE prior to analysis by reversed phase HPLC. Quantitative analysis of the MPA-DNPH using prednisolone-DNPH as an internal standard were optimized on a Hypersil ODS column using acetonitrile : methanol : 30 mM phosphate buffer, pH 3.0 (39 : 39 : 22, v/v/v) as mobile phase at a flow-rate of 1.0 mL/min. It was found that the method was selective and gave linear calibration curve for a concentration range of 1.0 - 10.0 ng/mL for 2 mL spiked plasma samples. The relative standard deviation (RSD) of inter-day precision for a period of three validation days was 11.5 + 3.4% for all concentration used. The RSD of intra-day precision (n = 5) was 5.05 + 2.7% with accuracy (n = 5) of 102.3 + 7.4%. The average recovery was found to be 102.9 + 4.4%. The correlation coefficient of the calibration curve was 0.9985. The limits of detection and quantitation were found to be 0.2 and 1.0 ng/mL, respectively. Using DNPH as a derivatizing agent can enhance both selectivity and sensitivity of MPA in plasma and is suitable for routine analysis.
GC-ECD:Gas chromatography-electron capture detection
GC-MS:Gas chromatography-mass spectrometry
HPLC-UV:High-performance liquid chromatography with ultraviolet detection
HPLC-PO-Cl:High-performance liquid chromatography with peroxyoxalate chemiluminescence
LC-MS/MS:Liquid chromatography-mass spectrometry/mass spectrometry
LOD:Limit of detection
LOQ:Limit of quantitation
MPA: Medroxyprogesterone acetate
MPA-DNPH: Medroxyprogesterone acetate-2,4-Dinitrophenylhydrazone
mg/mL:Milligram per milliliter
ng/mL:Nanogram per milliliter
RP-HPLC-AD: Reversed phase high-performance liquid chromatography with amperometric detection
RSD: Relative standard deviation
SD: Standard deviation
SPE: Solid-phase extraction
Liskin L. Quillin W. 1983Long-acting progestins-promise and prospects. Population Reports 2, K-18.
Fotherby K. Koetsawang S. Mathrutham M. 1980Pharmacokinetic study of different doses of Depoprovera. Contraception 22(5), 527-35.
Cromer B. A. Stager M. Bonny A. Lazebnik R. Rome E. Ziegler J. Debanne S. M. 2004Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolescent Health 35 434 41
Ohtsu T. Fujii H. Wakita H. Igarashi T. Itoh K. Imoto S. 1998Pharmacokinetic study of low-versus high-dose medroxyprogesterone acetate (MPA) in women. Cancer Chemother Pharmacol 42 1 8
Shimanker K. Saxena B. N. Fotherby K. A. 1978Radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem 9(4), 359-63.
Hesselius I. Johansson E. D. 1981Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study. Acta Obstet Gynecal Scand Suppl 101 65 70
Kaiser D. G. Carison R. G. Kirton K. T. 1974GLC [Gas-liquid chromatography] determination of medroxyprogesterone acetate in plasma. J Pharm Sci 83(3), 420-24.
Rossi E. Pascale A. D. Negrini P. Frigerio H. Castegnaro E. 1979Quantitative gas-liquid chromatographic determination of medroxyprogesterone acetate in human plasma. J Chromatogr 169 416 21
Milano G. Carle G. Rence N. Boublil J. L. Namer M. 1982Determination of medroxyprogesterone acetate in plasma by high-performance liquid chromatography. J Chromatogr 232 413 17
Read J. Mould G. Stevenson D. 1985Simple high-performance liquid chromatographic method for the determination of medroxyprogesterone acetate in human plasma. J Chromatogr 341 437 44
Dikkeschei L. D. Veclen H. V. Nagel G. T. Willemse P. H. B. Walthers B. G. 1985Specific and sensitive determination of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry. J Chromatogr 345 1 10
Gamberini G. Ferioli V. 1988Determination of medroxyprogesterone acetate in human plasma by high-performance liquid chromatography. Att Dellta Societa dei Naturalistie Matematici di Modena 118 119 24
Uzu S. Imai K. Nakashima K. Akiyama S. 1992Determination of medroxyprogesterone acetate in serum by HPLC with peroxyoxalate chemiluminescence detection using a fluorogenic reagent, 4-(N,N-dimethylaminosulphonyl)-7-hydrazino- 2 1 3benzoxadiazole. J Pharm and Biomed Anal 10, 979-84.
Kim S. M. Kim D. H. 2001Quantitative determination of medroxyprogesterone acetate in plasma by liquid chromatography / electrospray ion trap mass spectrometry. Rapid Communications in Mass Spectro 15(21), 2041-2.
Bond A. M. Hollenkamp A. F. Thompson S. B. Bourne A. R. Huf P. A. Watson T. G. 1988Analytical and mechanistic aspects of the electrochemical oxidation of keto steroids derivatized with phenylhydrazine, (4-nitrophenyl)hydrazine, and ( 2 4dinitrophenyl)hydrazine. Anal Chem 60, 1023-27.
Shimada K. J. Matsue T. Shimada K. Z. 1999Reagents for electrochemical detection. In: Modern Derivatization Methods for Separation Sciences (edited by T. Toyo Oka), 191 211John Wiley & Sons: New York, U.S.A.
Snyder L. R. Glajch J. L. Kirkland J. J. 1988Practical HPLC method development. Wiley-Interscience, New York, U.S.A.
Puputti E. Lehtonen P. 1986High-performance liquid chromatographic separation and diode-array spectroscopic identification of dinitrophenylhydrazone derivatives of carbonyl compounds from whiskies. J Chromatogr 353 163 68
Reich H. Grane K. F. Sanfilippo S. J. 1953The reaction of steroid ketones with 2 4dinitrophenylhydrazine. J Org Chem 18, 818-32.
Yang Q. Hartmann C. Verbeke J. J. Massart D. L. 1995Method development and validation for the determination of mineral elements in food and botanical materials by capillary electrophoresis. J Chromatogr 717 415 25
Hartmann C. Verbeke J. J. Massart D. L. Mc Dowall R. D. 1998Validation of pharmaceutical and biomedical chromatographic methods. J Pharm and Biomed Anal 17 193 218